ASH 2016 | What are the predictors of ponatinib treatment response?

Michael J. Mauro

Michael J. Mauro, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses his talk on predictors of ponatinib treatment response at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Mauro gives an overview of his study, which considered different characteristics of chronic myeloid leukemia (CML) patients receiving ponatinib treatment, to identify treatment outcome predictors. Preliminary data analysis was presented during ASH, including some factors that may predict for success of ponatinib therapy, such as mutation status, demographic and disease biology. This video has been supported by Incyte through an unrestricted educational grant.

Share this video